#

Dailypharm Live Search Close
  • Scemblix is listed in July
  • by Lee, Tak-Sun | translator Kim, Jung-Ju | Jun 23, 2023 05:45am
4th generation chronic myelogenous leukemia new drug
Establishment of reimbursement criteria for anticancer drugs, reimbursement for 3rd or higher monotherapy
 ¡ã Novartis 4th generation chronic myelogenous leukemia treatment Scemblix
Novartis' 4th-generation chronic myelogenous leukemia drug Scemblix is expected to be listed for reimbursement in July. This drug is used as monotherapy for 3 or more lines, and reimbursement is applied when used in patients with chronic myelogenous leukemia aged 18 years or older. On the 22nd, HIRA announced the revision of the reimbursement criteria for anti-cancer therapy.

Scemblix is covered for treating patients with chronic myeloid leukemia aged 18 years or older who are Philadelphia chromosome-positive in the chronic phase and who have previously been resistant or intolerant to two or more TKIs. The administration stage is 3rd or higher, but benefits are recognized if there is no T315I or V299L mutation. Sc
  • 0
Reader Comment
0
Anonymity comment Write Operate Rule
Colse

´ñ±Û ¿î¿µ¹æ½ÄÀº

´ñ±ÛÀº ½Ç¸í°ÔÀç¿Í À͸í°ÔÀç ¹æ½ÄÀÌ ÀÖÀ¸¸ç, ½Ç¸íÀº À̸§°ú ¾ÆÀ̵𰡠³ëÃâµË´Ï´Ù. À͸íÀº ÇʸíÀ¸·Î µî·Ï °¡´ÉÇϸç, ´ë´ñ±ÛÀº À͸íÀ¸·Î µî·Ï °¡´ÉÇÕ´Ï´Ù.

´ñ±Û ³ëÃâ¹æ½ÄÀº

´ñ±Û ¸í¿¹ÀÚ¹®À§¿ø(ÆÊ-ÄڴϾð-Çʱâ¸ð¾ç ¾ÆÀÌÄÜ)À¸·Î À§ÃËµÈ µ¥Àϸ®ÆÊ ȸ¿øÀÇ ´ñ±ÛÀº ¡®°Ô½ÃÆÇÇü º¸±â¡¯¿Í ¡¯ÆîÃ帱âÇü¡¯ ¸®½ºÆ®¿¡¼­ Ç×»ó ÃÖ»ó´Ü¿¡ ³ëÃâµË´Ï´Ù. »õ·Î¿î ´ñ±ÛÀ» ¿Ã¸®´Â ÀϹÝȸ¿øÀº ¡®°Ô½ÃÆÇÇü¡¯°ú ¡®ÆîÃ帱âÇü¡¯ ¸ðµÎ ÆÊÄڴϾð ȸ¿øÀÌ ¾´ ´ñ±ÛÀÇ ÇÏ´Ü¿¡ ½Ç½Ã°£ ³ëÃâµË´Ï´Ù.

´ñ±ÛÀÇ »èÁ¦ ±âÁØÀº

´ÙÀ½ÀÇ °æ¿ì »çÀü Å뺸¾øÀÌ »èÁ¦ÇÏ°í ¾ÆÀ̵ð ÀÌ¿ëÁ¤Áö ¶Ç´Â ¿µ±¸ °¡ÀÔÁ¦ÇÑÀÌ µÉ ¼öµµ ÀÖ½À´Ï´Ù.

  • ÀúÀ۱ǡ¤ÀÎ°Ý±Ç µî ŸÀÎÀÇ ±Ç¸®¸¦ Ä§ÇØÇÏ´Â °æ¿ì

    »ó¿ë ÇÁ·Î±×·¥ÀÇ µî·Ï°ú °ÔÀç, ¹èÆ÷¸¦ ¾È³»ÇÏ´Â °Ô½Ã¹°

    ŸÀÎ ¶Ç´Â Á¦3ÀÚÀÇ ÀúÀÛ±Ç ¹× ±âŸ ±Ç¸®¸¦ Ä§ÇØÇÑ ³»¿ëÀ» ´ãÀº °Ô½Ã¹°

  • ±Ù°Å ¾ø´Â ºñ¹æ¡¤¸í¿¹¸¦ ÈѼÕÇÏ´Â °Ô½Ã¹°

    ƯÁ¤ ÀÌ¿ëÀÚ ¹× °³Àο¡ ´ëÇÑ ÀνŠ°ø°ÝÀûÀÎ ³»¿ëÀÇ ±Û ¹× Á÷Á¢ÀûÀÎ ¿å¼³ÀÌ »ç¿ëµÈ °æ¿ì

    ƯÁ¤ Áö¿ª ¹× Á¾±³°£ÀÇ °¨Á¤´ë¸³À» Á¶ÀåÇÏ´Â ³»¿ë

    »ç½Ç È®ÀÎÀÌ ¾ÈµÈ ¼Ò¹®À» À¯Æ÷ ½ÃŰ´Â °æ¿ì

    ¿å¼³°ú ºñ¾î, ¼Ó¾î¸¦ ´ãÀº ³»¿ë

    Á¤´ç¹ý ¹× °øÁ÷¼±°Å¹ý, °ü°è ¹ý·É¿¡ ÀúÃ˵Ǵ °æ¿ì(¼±°üÀ§ ¿äû ½Ã Áï½Ã »èÁ¦)

    ƯÁ¤ Áö¿ªÀ̳ª ´Üü¸¦ ºñÇÏÇÏ´Â °æ¿ì

    ƯÁ¤ÀÎÀÇ ¸í¿¹¸¦ ÈѼÕÇÏ¿© ÇØ´çÀÎÀÌ »èÁ¦¸¦ ¿äûÇÏ´Â °æ¿ì

    ƯÁ¤ÀÎÀÇ °³ÀÎÁ¤º¸(Áֹεî·Ï¹øÈ£, ÀüÈ­, »ó¼¼ÁÖ¼Ò µî)¸¦ ¹«´ÜÀ¸·Î °Ô½ÃÇÏ´Â °æ¿ì

    ŸÀÎÀÇ ID ȤÀº ´Ð³×ÀÓÀ» µµ¿ëÇÏ´Â °æ¿ì

  • °Ô½ÃÆÇ Ư¼º»ó Á¦ÇѵǴ ³»¿ë

    ¼­ºñ½º ÁÖÁ¦¿Í ¸ÂÁö ¾Ê´Â ³»¿ëÀÇ ±ÛÀ» °ÔÀçÇÑ °æ¿ì

    µ¿ÀÏ ³»¿ëÀÇ ¿¬¼Ó °ÔÀç ¹× ¿©·¯ ±â»ç¿¡ Áߺ¹ °ÔÀçÇÑ °æ¿ì

    ºÎºÐÀûÀ¸·Î º¯°æÇÏ¿© ¹Ýº¹ °ÔÀçÇÏ´Â °æ¿ìµµ Æ÷ÇÔ

    Á¦¸ñ°ú °ü·Ã ¾ø´Â ³»¿ëÀÇ °Ô½Ã¹°, Á¦¸ñ°ú º»¹®ÀÌ ¹«°üÇÑ °æ¿ì

    µ·¹ú±â ¹× Á÷¡¤°£Á¢ »ó¾÷Àû ¸ñÀûÀÇ ³»¿ëÀÌ Æ÷ÇÔµÈ °Ô½Ã¹°

    °Ô½Ã¹° Àбâ À¯µµ µîÀ» À§ÇØ ³»¿ë°ú ¹«°üÇÑ Á¦¸ñÀ» »ç¿ëÇÑ °æ¿ì

  • ¼ö»ç±â°ü µîÀÇ °ø½ÄÀûÀÎ ¿äûÀÌ ÀÖ´Â °æ¿ì

  • ±âŸ»çÇ×

    °¢ ¼­ºñ½ºÀÇ Çʿ伺¿¡ µû¶ó ¹Ì¸® °øÁöÇÑ °æ¿ì

    ±âŸ ¹ý·ü¿¡ ÀúÃ˵Ǵ Á¤º¸ °ÔÀ縦 ¸ñÀûÀ¸·Î ÇÒ °æ¿ì

    ±âŸ ¿ø¸¸ÇÑ ¿î¿µÀ» À§ÇØ ¿î¿µÀÚ°¡ ÇÊ¿äÇÏ´Ù°í ÆÇ´ÜµÇ´Â ³»¿ë

  • »ç½Ç °ü°è È®ÀÎ ÈÄ »èÁ¦

    ÀúÀÛ±ÇÀڷκÎÅÍ Çã¶ô¹ÞÁö ¾ÊÀº ³»¿ëÀ» ¹«´Ü °ÔÀç, º¹Á¦, ¹èÆ÷ÇÏ´Â °æ¿ì

    ŸÀÎÀÇ ÃÊ»ó±ÇÀ» Ä§ÇØÇϰųª °³ÀÎÁ¤º¸¸¦ À¯ÃâÇÏ´Â °æ¿ì

    ´ç»ç¿¡ Á¦°øÇÑ ÀÌ¿ëÀÚÀÇ Á¤º¸°¡ ÇãÀ§ÀÎ °æ¿ì (ŸÀÎÀÇ ID, ºñ¹Ð¹øÈ£ µµ¿ë µî)

  • ¡ØÀÌ»óÀÇ ³»¿ëÁß ÀϺΠ»çÇ׿¡ Àû¿ëµÉ °æ¿ì ÀÌ¿ë¾à°ü ¹× °ü·Ã ¹ý·ü¿¡ ÀÇÇØ Á¦À縦 ¹ÞÀ¸½Ç ¼öµµ ÀÖÀ¸¸ç, ¹Î¡¤Çü»ç»ó ó¹úÀ» ¹ÞÀ» ¼öµµ ÀÖ½À´Ï´Ù.

    ¡ØÀ§¿¡ ¸í½ÃµÇÁö ¾ÊÀº ³»¿ëÀÌ´õ¶óµµ ºÒ¹ýÀûÀÎ ³»¿ëÀ¸·Î ÆÇ´ÜµÇ°Å³ª µ¥Àϸ®ÆÊ ¼­ºñ½º¿¡ ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì´Â ¼± Á¶Ä¡ ÀÌÈÄ º» °ü¸® ±âÁØÀ» ¼öÁ¤ °ø½ÃÇϰڽÀ´Ï´Ù.

    ¡Ø±âŸ ¹®ÀÇ »çÇ×Àº µ¥Àϸ®ÆÊ ¿î¿µÀÚ¿¡°Ô ¿¬¶ôÁֽʽÿÀ. ¸ÞÀÏ ÁÖ¼Ò´Â dailypharm@dailypharm.comÀÔ´Ï´Ù.

Write
Write
recently Agree DisAgree
If you want to see the full article, please JOIN US (click)